Clinical Trial Update: Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout [Phase 3]

View source ↗

Summary

A Phase 3 double-blind study evaluating FYU-981 (febuxostat-controlled) in hyperuricemia with or without gout has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia with or Without Gout

Drugs mentioned

• FYU-981

Snippet

Sponsor: Mochida Pharmaceutical Company, Ltd. | Conditions: Hyperuricemia With or Without Gout | Phase 3 | Status: COMPLETED